COMMUNIQUÉS West-GlobeNewswire

VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16

10/04/2018 - 14:00

TEL AVIV, Israel, April 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]

CareDx Launches HeartCare® for Heart Transplant Recipients

10/04/2018 - 14:00

HeartCare combines AlloMap and AlloSure-Heart for Comprehensive Rejection Surveillance BRISBANE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ), a molecular diagnostics company focused on the [...]

ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium

10/04/2018 - 14:00

NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been invited to present as [...]

Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia

10/04/2018 - 14:00

BASKING RIDGE, N.J., April 10, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS ) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms [...]

Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA

10/04/2018 - 14:00

EXTON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]

Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress

10/04/2018 - 14:00

3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less frequent dosing compared with recent data [...]

VANC Names Lampyon as Its Marketing and Creative Agency of Record

10/04/2018 - 14:00

VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“ VANC ”) is pleased to announce that it has selected and entered into a service agreement with Lampyon Canada Inc. (“ Lampyon [...]

Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders

10/04/2018 - 14:00

CAMBRIDGE, Mass. and TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE ), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically- [...]

GTX Corp Finishes Delivery of Initial Military Order and Comments on 2017 Financial Results

10/04/2018 - 14:00

LOS ANGELES, April 10, 2018 (GLOBE NEWSWIRE) -- GTX Corp (OTCBB: GTXO ) , an Internet of Things (IoT) solutions provider in the personal location, wearable and wandering assistive technology business, announced today [...]

Inovalon Launches Clinical Data Extraction as a Service and Natural Language Processing as a Service on the Inovalon ONE™ Platform

10/04/2018 - 13:55

Capabilities Enable Fully Automated Capture of Structured and Unstructured Clinical Data at Large Scale, Improving Quality and Eliminating Expensive and Time-Consuming Processes for Clients BOWIE, Md., April 10, 2018 ( [...]

Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

10/04/2018 - 13:30

RICHMOND HILL, Ontario, April 10, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP ) (FRANKFURT: HBP ) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates [...]

Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting

10/04/2018 - 13:00

La Chaux-de-Fonds, Switzerland, April 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and RP10107, a novel and [...]

ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

10/04/2018 - 13:00

Key Updates Dr. Peter A. Beal joins ProQR’s scientific advisory board, bringing with him tremendous experience in the field of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field [...]

Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation

10/04/2018 - 13:00

STAMFORD, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs

10/04/2018 - 13:00

Successful broad signal-seeking efforts identify T-cell lymphoma as an indication responsive to TTI-621 therapy. Focusing TTI-621 intravenous trial on separate cutaneous and peripheral T-cell lymphoma cohorts employing [...]

BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma

10/04/2018 - 13:00

CAMBRIDGE, Mass. and BEIJING, China, April 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial

10/04/2018 - 13:00

TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for [...]

Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)

10/04/2018 - 13:00

DEVON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative [...]

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

10/04/2018 - 13:00

GERMANTOWN, Md., April 10, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today [...]